You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 14, 2025

Drugs in MeSH Category Gasotransmitters


✉ Email this page to a colleague

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mallinckrodt Hosp INOMAX nitric oxide GAS;INHALATION 020845-002 Dec 23, 1999 DISCN Yes No 8,282,966*PED ⤷  Try for Free Y ⤷  Try for Free
Vero Biotech Inc GENOSYL nitric oxide GAS;INHALATION 202860-001 Dec 20, 2019 RX Yes Yes 8,226,916 ⤷  Try for Free ⤷  Try for Free
Mallinckrodt Hosp INOMAX nitric oxide GAS;INHALATION 020845-003 Dec 23, 1999 AA RX Yes Yes 8,293,284*PED ⤷  Try for Free Y ⤷  Try for Free
Mallinckrodt Hosp INOMAX nitric oxide GAS;INHALATION 020845-003 Dec 23, 1999 AA RX Yes Yes 9,265,911*PED ⤷  Try for Free Y ⤷  Try for Free
Mallinckrodt Hosp INOMAX nitric oxide GAS;INHALATION 020845-003 Dec 23, 1999 AA RX Yes Yes 8,846,112*PED ⤷  Try for Free Y ⤷  Try for Free
Mallinckrodt Hosp INOMAX nitric oxide GAS;INHALATION 020845-004 Jan 17, 2023 RX Yes Yes 11,931,377 ⤷  Try for Free Y Y ⤷  Try for Free
Airgas Therap ULSPIRA nitric oxide GAS;INHALATION 203144-001 Jul 27, 2023 AA RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Gasotransmitters Market Analysis and Financial Projection

Last updated: March 24, 2025

The market dynamics and patent landscape for gasotransmitter-related drugs reflect a rapidly evolving field driven by therapeutic potential and technological innovation. Below is a structured analysis:


Market Dynamics

Therapeutic Potential:
Nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H₂S) are central to cardiovascular, neurological, and immune regulation. Their roles in treating chronic wounds, ischemia, and bacterial infections[7][15] have spurred R&D investment. For example, NO’s vasodilatory properties and H₂S’s angiogenic effects[7][17] are being leveraged for organ transplantation and regenerative medicine.

Key Growth Drivers:

  1. Delivery System Innovation:

    • Hydrogels[7], polymers[12][15], and electrochemical generators[2] address challenges like short half-life and systemic toxicity.
    • Gas-powered injectors (e.g., Kaléo’s Aerio, CrossJect’s ZENEO) enable high-volume delivery of viscous biologics[9].
  2. Drug Repurposing:

    • Statins and resveratrol exhibit secondary gasotransmitter-mediated effects, expanding their therapeutic applications[17].
  3. Biomedical Applications:

    • Focus areas include tissue engineering[11], antimicrobial therapies[7], and cardiovascular interventions[17].

Challenges:

  • Toxicity risks at high concentrations[1][15].
  • Need for localized delivery to minimize off-target effects[7][12].

Patent Landscape

Key Innovation Areas: Category Examples Patent Trends
Synthesis Electrochemical in situ generation[2], hybrid molecules combining NO/H₂S donors[3] Rising filings for enzyme-stable intermediates[10].
Delivery Systems PLGA/polymer-controlled release[12][15], hydrogels[7], microneedle arrays[9] Dominated by formulations targeting burst reduction[15].
Combination Therapies Hybrid drugs integrating gasotransmitters with anti-inflammatories or antioxidants[3][11] Growing interest in synergistic effects[3].

Leading Players:

  • Device Developers: Kaléo, CrossJect, and Altaviz (gas-powered injectors)[9].
  • Pharmaceutical Firms: Pfizer (combination therapies)[13], Novo Nordisk (delivery partnerships)[9].
  • Academic Institutions: Research on polymer-based delivery systems[12][15].

Geographical Trends:

  • US and Europe lead in electrochemical/hydrogel patents[2][7].
  • Asia-Pacific emerging in polymer-based delivery[12].

Licensing and Accessibility:

  • Voluntary licenses (e.g., Medicines Patent Pool agreement for Paxlovid[13]) may influence generic production in low-income regions.

Future Directions

  1. Targeted Delivery: Nanoparticles and stimuli-responsive hydrogels to minimize off-target effects[7][12].
  2. Clinical Translation: Dose optimization studies to balance efficacy and toxicity[11][15].
  3. Regulatory Frameworks: Harmonizing approval processes for novel delivery platforms[9][13].
"Advances in injection technologies... can reduce injection-site pain and improve patient adherence." – *ONdrugDelivery, 2025*[9]

Key Takeaways:

  • Gasotransmitter therapeutics are transitioning from experimental to clinical stages, fueled by delivery innovations.
  • Patent activity underscores a race to protect synthesis methods and localized delivery technologies.
  • Market growth hinges on overcoming pharmacokinetic challenges and expanding therapeutic indications.

References

  1. https://en.wikipedia.org/wiki/Gasotransmitter
  2. https://patents.google.com/patent/US20180221210A1/en
  3. https://pubmed.ncbi.nlm.nih.gov/32224139/
  4. https://mdpi-res.com/bookfiles/book/4220/Advanced_Materials_in_Drug_Release_and_Drug_Delivery_Systems.pdf?v=1738980240
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC5061972/
  6. https://openagriculturejournal.com/VOLUME/16/ELOCATOR/e187433152207050/FULLTEXT/
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC11180494/
  8. https://dergi.fabad.org.tr/wp-content/uploads/2023/10/48-03-00-Tamami.pdf
  9. https://www.ondrugdelivery.com/drug-delivery-trends-for-2025/
  10. https://www.wipo.int/edocs/pubdocs/en/patents/946/wipo_pub_946.pdf
  11. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2017.00659/full
  12. https://cris.maastrichtuniversity.nl/files/241149367/s8627.pdf
  13. https://www.citizen.org/wp-content/uploads/Paxlovid-Patent-Landscape-Feb-16-final-website.pdf
  14. https://law.resource.org/pub/us/works/Phase1Searches/Data/WebOfScience/NIHSearch01.WOS.0065.4.19.ris
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC4113624/
  16. https://pubmed.ncbi.nlm.nih.gov/20865561/
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC3038605/

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.